Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Kentucky for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Kentucky only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Kentucky (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rachel Chase (NPI 1518052893)

Field	Value
Entity Type	Individual
Organization	Rachel Chase
Address	100 E Liberty St Ste 700
City	Louisville
State	KY
ZIP	40202
Taxonomy	Rheumatology Physician
NPI Enumerated	October 4, 2006

Payer Source	Total Paid
Medicare	$4.8M
Medicaid	$0

Key Findings

This provider is highly specialized in infused biological therapies and oncology-support infusions: the top revenue codes are biologic injectable drugs (J0129, J0717, Q5104) and several infliximab/rituximab/tocilizumab codes, plus chemotherapy administration codes (96413, 96401, 96415). The CPT/HCPCS mix indicates a practice model centered on in-office IV administration of high-cost specialty drugs and chemotherapy/infusion services rather than a primary-care or procedure-only workflow.

Medicare revenue is the sole documented public-payer source for this provider: total Medicare revenue is $4.8M while there is no Medicaid billing on file. This makes the provider effectively single-payer (Medicare) in the available government claims data and implies Medicaid is not a material part of their publicly billed revenue mix.

Revenue concentration is high: the precomputed top-3 Medicare codes account for 60.1% of total Medicare revenue. That concentration shows the practice depends heavily on a small set of infusion drug codes for the majority of its Medicare receipts, increasing sensitivity to utilization or reimbursement changes for those agents.

The provider is an extreme national outlier for several specific biologic and infusion-related codes. Q5104 ranks #1 of 178 providers nationally (100th percentile; extreme outlier) and J0129 ranks #22 of 1221 (98th percentile; extreme outlier), indicating volumes for those biosimilar and biologic infusions are far above typical national providers. Additionally, 96413 and 96415 both appear at the 100th percentile nationally for administration activity, reinforcing unusually high infusion throughput.

Other high-revenue drug codes also show above-typical national positioning: J0717 ranks #30 of 848 providers nationally (97th percentile; notably above typical national volume) and J1745 ranks #26 of 1352 providers nationally (98th percentile; notably above typical national volume). These rankings collectively indicate the provider is a major national-level participant for multiple specific injectable biologics.

Clinical visit volumes for evaluation-and-management codes are modest relative to infusion codes: 99215 is present with 756 claims and $90K revenue but is noted as an extreme outlier nationally (100th percentile) by rank, whereas other E/M codes such as 99214 and 99213 are at more typical percentiles. This suggests the practice mix emphasizes procedure/drug administration revenue while maintaining some high-acuity office visit activity.

Tenure in the NPI registry is long: the NPI was enumerated on 2006-10-04, approximately 20 years ago. The extended active period is consistent with an established infusion/biologics practice and may reflect sustained specialty services in the Louisville market.

Although many lower-revenue codes appear at typical national percentiles (for example J3262 at the 70th percentile and J0897 at the 82th percentile), the combination of extreme outlier rankings for specific biosimilars/biologics plus high chemotherapy administration ranks positions the provider as a concentrated, high-volume infusion center within Medicare. This profile suggests market differentiation based on in-office biologic/infusible therapy capacity rather than broad primary-care throughput.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

28 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	37,500	$30	$1.3M
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	208,000	$1	$832K
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	27,480	$30	$824.5K
J1602	Injection, golimumab, 1 mg, for intravenous use	43,000	$10	$430K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	15,290	$30	$397.5K
J3262	Injection, tocilizumab, 1 mg	58,740	$10	$293.7K
J9312	Injection, rituximab, 10 mg	2,800	$60	$165.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,630	$90	$151.6K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	6,070	$20	$133.5K
J0897	Injection, denosumab, 1 mg	7,320	$20	$131.8K

Showing 1–10 of 28

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 28 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Kentucky Distribution

Rachel Chase — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Kentucky

Full comparison — all codes billed, vs. state median

28 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	1	30	9,700	$30	$415.4K
Q5104	1	10	1,920	$30	$308.8K
J0717	4	30	46,400	$1	$288.1K
J3262	4	10	33,960	$1	$183.8K
J9312	2	10	2,850	$60	$174.1K
J1602	1	20	11,560	$10	$141.6K
Q5119	1	10	6,070	$20	$135.8K
J1745	1	10	2,010	$30	$93.6K
J0897	8	80	2,280	$20	$59.6K
96413	1	50	100	$90	$16.7K

Showing 1–10 of 28

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rachel Chase, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dana Mann	KY	Family Nurse Practitioner	$824.8K	$0
Steven Stern	KY	Rheumatology Physician	$382.3K	$0
Rachel Wate	IN	Nurse Practitioner	$162.6K	$0
Felix Olash	KY	Internal Medicine Physician	$85.9K	$0

Nearby Providers

Other providers in the same ZIP code as Rachel Chase, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Norton Hospitals Inc	KY	General Acute Care Hospital	$0	$419.8M
Norton Hospitals, Inc	KY	General Acute Care Hospital	$0	$299.3M
Uofl Health-louisville Inc	KY	General Acute Care Hospital	$0	$283.3M
University Medical Center, Inc	KY	General Acute Care Hospital	$0	$179.5M
Verralab Ja LLC	KY	Clinical Medical Laboratory	$304.7K	$38.8M
University Medical Associates	KY	Internal Medicine Physician	$0	$17.3M
Ocean Behavioral Healthcare LLC	KY	Clinical Social Worker	$0	$11.9M
University Emergency Medicine Associates P.s.c.	KY	Emergency Medicine Physician	$0	$11.8M
Recovery Chestnut, LLC	KY	Addiction (Substance Use Disorder) Counselor	$0	$10.9M
Green House Recovery And Rehabilitation Center	KY	Multi-Specialty Clinic/Center	$0	$10.6M

Rachel Chase — Billing Profile & Reimbursement Data

Sign up for Rachel Chase — Billing Profile & Reimbursement Data policy alerts

Rachel Chase — Billing Profile & Reimbursement Data

Sign up for Rachel Chase — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References